By Sabela Ojea
Shares of Ardelyx rose after the company disclosed that its chairman, David Mott, has increased its stake in the company.
The stock was up 7.1%, to $5.41, in Wednesday post-market trading. Through the close, shares have dropped 41% over the past 12 months.
Mott, who has served as the biotechnology's chairman of the board since 2009, acquired 199,000 shares in the company, according to a Securities and Exchange Commission filing.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 22, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.